Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick P Gleason

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
The Annals of Pharmacotherapy|January 13, 2005
Are incentive-based formularies inversely associated with drug utilization in managed care?Patrick P Gleason, Brent W Gunderson, Kristin R Gericke
Journal of Managed Care Pharmacy : JMCP|July 20, 2010
Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasisJeremy A Schafer, Nicole K Kjesbo, Patrick P Gleason
Journal of Managed Care Pharmacy : JMCP|June 4, 2010
Pharmacy students' views of managed care pharmacy and PBMS: should there be more exposure to managed care in the pharmacy curriculum?Amy L Pittenger, Catherine I Starner, Kaj Thompson, et al.
Journal of Managed Care Pharmacy : JMCP|July 4, 2007
Telithromycin: the perils of hasty adoption and persistence of off-label prescribingPatrick P Gleason, Carol Walters, Alan H Heaton, et al.
Healthcare (Amsterdam, Netherlands)|September 18, 2016
Impact of provider mailings on medication adherence by Medicare Part D membersBijan J Borah, Yang Qiu, Nilay D Shah, et al.
Journal of Managed Care & Specialty Pharmacy|June 5, 2023
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosisLandon Z Marshall, Rachel Espinosa, Catherine I Starner, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort StudyCatherine I Starner, Yang Qiu, Pinar Karaca-Mandic, et al.
Journal of Managed Care & Specialty Pharmacy|July 31, 2023
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuriaKelly C Broderick, James P Burke, Jesse Fishman, et al.
Journal of Managed Care Pharmacy : JMCP|April 4, 2012
Rosiglitazone prior authorization safety policy: a cohort studyCatherine I Starner, Beckie Fenrick, John Coleman, et al.
Pharmacotherapy|July 12, 2005
Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization programPatrick P Gleason, Clint Williams, Sally Hrdy, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
The Annals of Pharmacotherapy|January 13, 2005
Are incentive-based formularies inversely associated with drug utilization in managed care?Patrick P Gleason, Brent W Gunderson, Kristin R Gericke
Journal of Managed Care Pharmacy : JMCP|July 20, 2010
Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasisJeremy A Schafer, Nicole K Kjesbo, Patrick P Gleason
Journal of Managed Care Pharmacy : JMCP|June 4, 2010
Pharmacy students' views of managed care pharmacy and PBMS: should there be more exposure to managed care in the pharmacy curriculum?Amy L Pittenger, Catherine I Starner, Kaj Thompson, et al.
Journal of Managed Care Pharmacy : JMCP|July 4, 2007
Telithromycin: the perils of hasty adoption and persistence of off-label prescribingPatrick P Gleason, Carol Walters, Alan H Heaton, et al.
Healthcare (Amsterdam, Netherlands)|September 18, 2016
Impact of provider mailings on medication adherence by Medicare Part D membersBijan J Borah, Yang Qiu, Nilay D Shah, et al.
Journal of Managed Care & Specialty Pharmacy|June 5, 2023
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosisLandon Z Marshall, Rachel Espinosa, Catherine I Starner, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort StudyCatherine I Starner, Yang Qiu, Pinar Karaca-Mandic, et al.
Journal of Managed Care & Specialty Pharmacy|July 31, 2023
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuriaKelly C Broderick, James P Burke, Jesse Fishman, et al.
Journal of Managed Care Pharmacy : JMCP|April 4, 2012
Rosiglitazone prior authorization safety policy: a cohort studyCatherine I Starner, Beckie Fenrick, John Coleman, et al.
Pharmacotherapy|July 12, 2005
Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization programPatrick P Gleason, Clint Williams, Sally Hrdy, et al.
Pageof 4